drugset / Trial / NCT01987284
SER100 in Isolated Systolic Hypertension
Phase 2
Completed
17 enrolled
Serodus AS
Smerud Medical Research International AS · collabThe Research Council of Norway · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
Isolated Systolic Hypertension (ISH)is the dominating hypertensive disease in elderly people. Much attention has recently been drawn to the strong relationship between the systolic blood pressure and cardiovascular morbidity. In previous clinical studies carried out in individuals with normal blood pressure at baseline SER100 decreased primarily the systolic blood pressure. It is hypothesized that the effect on systolic blood pressure in hypertensive patients will be larger or equal to the fall seen in normotensive patients.
Timeline
- Start
- 2013-10
- Primary completion
- 2014-07
- Completion
- 2014-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SER100 | Protein / enzyme biologic | 10 mg | Subcutaneous |
Indications
No indication recorded.